Joel E. Gallant
#161,623
Most Influential Person Now
Joel E. Gallant's AcademicInfluence.com Rankings
Joel E. Gallantphilosophy Degrees
Philosophy
#9341
World Rank
#12884
Historical Rank
Logic
#6321
World Rank
#7830
Historical Rank
Joel E. Gallantbiology Degrees
Biology
#12842
World Rank
#16345
Historical Rank
Immunology
#865
World Rank
#888
Historical Rank
Download Badge
Philosophy Biology
Joel E. Gallant's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Immunology University of California, San Francisco
Why Is Joel E. Gallant Influential?
(Suggest an Edit or Addition)Joel E. Gallant's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. (1997) (2876)
- Prevention of HIV-1 infection with early antiretroviral therapy. (2011) (2213)
- Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy (1999) (2106)
- Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. (2004) (1460)
- Antiretroviral Therapy for the Prevention of HIV-1 Transmission. (2016) (1154)
- The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation (2010) (1129)
- Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. (2006) (940)
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. (2016) (753)
- Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. (1992) (546)
- Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. (2004) (518)
- Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. (2014) (445)
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks (2012) (436)
- Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. (2014) (435)
- Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells (2006) (403)
- Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. (2005) (389)
- Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. (2014) (389)
- Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. (2003) (385)
- Antiretroviral therapy. (2000) (366)
- Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials (2014) (330)
- Medical Management of HIV Infection (1996) (326)
- Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. (2005) (304)
- Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. (2014) (254)
- Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis (2006) (248)
- Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis (2008) (244)
- Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users (2001) (200)
- The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. (2002) (194)
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial (2017) (192)
- Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. (2007) (190)
- Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. (2005) (190)
- Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. (2004) (190)
- Impact of opportunistic disease on survival in patients with HIV infection (1998) (187)
- Antiretroviral therapy in the treatment of HIV-associated nephropathy. (2006) (165)
- Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. (2005) (159)
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. (2017) (154)
- Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. (1997) (153)
- Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. (1996) (153)
- Comorbidities Among US Patients With Prevalent HIV Infection—A Trend Analysis (2017) (151)
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy (2003) (151)
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results (2013) (147)
- Renal function with use of a tenofovir-containing initial antiretroviral regimen (2009) (140)
- Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. (2016) (133)
- Strategies for long-term success in the treatment of HIV infection. (2000) (132)
- The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients (2008) (125)
- Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings (2012) (125)
- Prophylaxis for Opportunistic Infections in Patients with HIV Infection (1994) (121)
- Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. (2006) (119)
- Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. (2013) (119)
- Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure (2018) (116)
- Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients (2007) (114)
- HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. (2012) (114)
- Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. (1996) (113)
- Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care (2020) (111)
- A Systematic Review of HIV/AIDS Survival and Delayed Diagnosis Among Hispanics in the United States (2012) (106)
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results (2014) (99)
- Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. (1997) (95)
- Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs (2011) (92)
- Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia (2002) (88)
- Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults (2008) (86)
- Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. (2004) (85)
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients (2004) (85)
- Comorbidities among HIV-infected injection drug users in Chennai, India. (2008) (81)
- Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition. (2011) (79)
- Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance (2002) (78)
- Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients (2011) (78)
- HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. (2006) (76)
- HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing (2015) (75)
- Initial therapy of HIV infection. (2002) (68)
- A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients (2018) (67)
- Renal safety of tenofovir disoproxil fumarate. (2007) (66)
- Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults (2017) (64)
- Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. (2003) (63)
- Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults (2017) (62)
- Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. (2001) (61)
- Antiretroviral drug resistance and resistance testing. (2005) (60)
- The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors (2008) (59)
- Host Factors Dictate Control of Viral Replication in two HIV-1 Controller/Chronic Progressor Transmission Pairs (2012) (59)
- Absolute CD4 Vs. CD4 Percentage for Predicting the Risk of Opportunistic Illness in HIV Infection (2004) (56)
- Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. (1999) (53)
- Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. (1996) (53)
- Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults (2016) (53)
- Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing (2004) (52)
- A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults (2017) (51)
- Risk factors for Kaposi's sarcoma among HHV‐8 seropositive homosexual men with AIDS (2005) (51)
- Tenofovir disoproxil fumarate (2003) (46)
- Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. (1999) (46)
- Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users (2004) (42)
- The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. (1998) (41)
- Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes (2007) (40)
- Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients. (1998) (39)
- Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. (2007) (35)
- Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use. (2002) (35)
- HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. (2009) (34)
- Protease-inhibitor boosting in the treatment-experienced patient. (2004) (34)
- Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? (2013) (34)
- High-Risk Behavior and Potential Transmission of Drug-Resistant HIV Among Injection Drug Users (2004) (30)
- Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. (1994) (29)
- A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk (2003) (29)
- Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine (2000) (28)
- Seronegative HIV-1 infection: a review of the literature (2010) (27)
- Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results (2015) (27)
- Incidence and Natural History of Cytomegalovirus Disease in Patients With Advanced Human Immune Deficiency Virus Disease Treated With Zidovudine: The Zidovudine Epidemiology Study Group (1993) (27)
- Risk Factors for Kaposi's Sarcoma in Patients With Advanced Human Immunodeficiency Virus Disease Treated With Zidovudine (1994) (25)
- Tenofovir disoproxil fumarate for the treatment of HIV infection (2006) (25)
- The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. (1995) (25)
- Risk factors for human herpesvirus 8 seropositivity in the AIDS Cancer Cohort Study. (2006) (23)
- MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure (2017) (23)
- HIV counseling, testing, and referral. (2004) (23)
- Discontinuation of Tenofovir Disoproxil Fumarate for Presumed Renal Adverse Events in Treatment-Naïve HIV-1 Patients: Meta-analysis of Randomized Clinical Studies (2014) (23)
- Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting (1993) (23)
- The M184V mutation: what it does, how to prevent it, and what to do with it when it's there. (2006) (22)
- Virologic outcomes in early antiretroviral treatment: HPTN 052 (2017) (22)
- High Frequency of Highly Active Antiretroviral Therapy Modifications in Patients with Acute or Early Human Immunodeficiency Virus Infection (2006) (20)
- Human Immunodeficiency Virus Medicine (2017) (19)
- Lack of Association between Acyclovir Use and Survival in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine (1995) (19)
- Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial (2021) (18)
- Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis (2018) (18)
- Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels. (2014) (18)
- Intramedullary tuberculoma in a patient with HIV infection. (1992) (18)
- Making sense of blips. (2007) (18)
- MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure (2017) (17)
- Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. (2012) (17)
- Human immunodeficiency virus infection and hospital mortality in acute lung injury patients (2010) (16)
- Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients. (1999) (16)
- Approach to the Treatment-experienced patient (2005) (15)
- Tolerability and Efficacy of PI Versus NNRTI-Based Regimens in Subjects Receiving HAART During Acute or Early HIV Infection (2009) (15)
- Hepatitis C Virus Testing in Adults Living with HIV: A Need for Improved Screening Efforts (2014) (15)
- Tipranavir. (2020) (15)
- Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial (2016) (14)
- Healthcare utilization and direct costs of non-infectious comorbidities in HIV-infected patients in the USA (2018) (12)
- Get Rich Quick With Old Generic Drugs! The Pyrimethamine Pricing Scandal (2015) (12)
- Tenofovir disoproxil fumarate (Viread®) for the treatment of HIV infection (2003) (12)
- Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients. (2002) (11)
- Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. (2021) (11)
- Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. (2020) (11)
- Reply to Gupta (2005) (11)
- Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring (2006) (11)
- Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor. (1995) (10)
- Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients (2012) (10)
- Respiratory insufficiency from dapsone-induced methemoglobinemia. (1991) (10)
- Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. (2020) (9)
- A case of seronegative HIV-1 infection. (2010) (9)
- When to start antiretroviral therapy: a swinging pendulum? (2008) (9)
- Raltegravir-induced cerebellar ataxia. (2010) (9)
- HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052 (2017) (9)
- Safety, Tolerability, and Antiretroviral Effects of Ritonavir‐Nelfinavir Combination Therapy Administered for 48 Weeks (2000) (9)
- Diagnostic accuracy of three clinical case definitions for advanced HIV disease (1992) (8)
- Osteomyelitis due to mycobacterium kansasii and mycobacterium avium complex in an HIV-infected patient (1994) (8)
- Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. (1997) (8)
- Current management challenges in HIV: antiretroviral resistance. (2003) (8)
- Nephrotoxicity of antiretroviral agents: is the list getting longer? (2013) (8)
- What does the generalist need to know about HIV infection? (2010) (7)
- Article Commentary: Dolutegravir Monotherapy: When Should Clinical Practice be Clinical Research? (2016) (7)
- Sande's HIV/AIDS Medicine: Medical Management of AIDS 2013: Second Edition (2012) (7)
- Should antiretroviral therapy be started earlier? (2007) (7)
- Current status of antiretroviral treatment interruption and intermittent therapy strategies. (2002) (6)
- Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States. (2017) (6)
- The Ryan White HIV/AIDS Program after the Patient Protection and Affordable Care Act full implementation: a critical review of predictions, evidence, and future directions. (2019) (6)
- Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years (2014) (6)
- Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2. (2010) (6)
- Strategic Simplification: The Efficacy and Safety of Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) in Treatment-Experienced HIV-1 Infected Adults (NCT01968551) (2015) (6)
- Fatal Granulomatous Amebic Encephalitis Due to Balamuthia mandrillaris in New Mexico: A Case Report (2014) (5)
- Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium (2022) (5)
- Approach to the treatment-experienced patient. (2007) (5)
- Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. (2009) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial§ (2017) (4)
- Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium (2020) (4)
- 100 Questions & Answers About HIV And AIDS (2007) (4)
- Eff ects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection : results from the phase 3 HPTN 052 randomised controlled trial (2014) (4)
- Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India (2013) (4)
- Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. (2000) (4)
- Guidelines for the Management of Persons Infected With HIV : 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2013) (4)
- Short communication: CD4 cell count increases during successful treatment of Graves' disease with methimazole in HIV-infected patients on antiretroviral therapy. (2012) (4)
- Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. (1995) (3)
- The Ideal Nucleoside/Nucleotide Backbone (2004) (3)
- Antiretroviral therapy update from the 44th ICAAC. (2005) (3)
- Evolving Treatment Strategies (2007) (3)
- Editorial comment: strategies for success--a return to "hit early"? (2004) (3)
- Papules and Nodules in a Patient With the Acquired Immunodeficiency Syndrome and Recurrent Cryptococcal Meningitis (1991) (3)
- Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age (2022) (3)
- Current perspectives on the nucleoside/nucleotide components of combination antiretroviral therapy. (2004) (3)
- Infectious complications of HIV disease. (1995) (3)
- Efficacy of Nelfinavir in Patients Switched from Ritonavir/Saquinavir Combination Antiretroviral Therapy (2000) (2)
- HIV Infection: Still a Disease for Experts. (2015) (2)
- When and how to use tipranavir and darunavir. (2007) (2)
- Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART (2005) (2)
- HIV Type 1 RNA Level as a Clinical Indicator of Renal Pathology in (2006) (2)
- Investigating new antiretroviral combinations. Author's reply (2006) (2)
- High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I (2022) (2)
- Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). The tenacity of NNRTI drug resistance. (2004) (2)
- Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus. (1996) (2)
- The efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF ('Quad') compared to efavirenz/emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects: primary results of study GS-US-236-0102 (2012) (2)
- Papules and nodules in a patient with the acquired immunodeficiency syndrome and recurrent cryptococcal meningitis. Bacillary angiomatosis or epithelioid angiomatosis. (1991) (2)
- Antiretroviral therapy in naïve patients. (2000) (2)
- Future of HIV/AIDS Care in Low- and Middle- Income Countries (2008) (2)
- International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
- When to start antiretroviral therapy? NA-ACCORD stimulates the debate. (2009) (2)
- Risk factors for Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and non-AIDS-defining cancers in the era of highly active anti-retroviral therapy (2005) (1)
- Article Commentary: Antiretroviral Therapy in Resource-Limited Settings: Is There Still a Role for Stavudine? (2012) (1)
- PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS. AUTHORS' REPLY (1995) (1)
- A proper introduction. (2011) (1)
- False positive viral load results: recent problems and solutions. (2005) (1)
- Selected Topics from the First International AIDS Society Conference July 8-11, 2001 Buenos Aires, Argentina (2001) (1)
- Drug Guide 2000: the antiretroviral agents. (2000) (1)
- Tenofovir, Equivalence, and Noninferiority—Reply (2004) (1)
- Track C Epidemiology and Prevention Science (2012) (1)
- A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection (2015) (1)
- Preaching to the choir: advocating routine HIV testing. (2009) (1)
- Erratum: Marked intraindividual variability in antiretrovrial concentrations may limit the utility of therapeutic drug monitoring (Clinical Infectious Diseases (April 15, 2006) 42 (1189-1196)) (2006) (1)
- Antiretroviral therapy in the treatment-experienced patient. (1999) (1)
- A Longitudinal Analysis of Cardiovascular and Fracture Rates Among HIV-Infected Patients in the USA With Commercial and Medicaid Insurance (2015) (1)
- Communications to the EditorThe Effect of Prophylaxis on the Outcome of HIV-Associated Pneumocystis carinii Pneumonia (1996) (1)
- Impact of the 1993 revision of the CDC case definition on the performance of the WHO and PAHO clinical case definitions for AIDS (1993) (1)
- Editorial comment: thoughts on the once-daily-dosing bandwagon. (2004) (1)
- Prophylaxis for Opportunistic Infections (1995) (1)
- When to consider corticosteroid therapy for HIV-infected patients (1999) (1)
- HIV drug guide introduction. A brief description of the drug classes and how they work. (2008) (1)
- The new drugs and how to use them. (1999) (1)
- Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial (2015) (1)
- XV International AIDS Conference in Bangkok: Antiretroviral Therapy (2004) (1)
- Safety and efficacy of elbasvir and grazoprevir with or without ribavirin for the treatment of hepatitis C virus genotype 1: results of the hepatitis C virus-TARGET study (2017) (1)
- Tenofovir, equivalence, and noninferiority. Authors' reply (2004) (1)
- 2012 HIV Drug Guide. (2012) (0)
- Antiretroviral therapy update. Everything you need to know, in a nutshell. (2008) (0)
- Initial regimens for the treatment-naive patient: current understanding and practice. (2008) (0)
- 12th annual HIV drug guide. (2008) (0)
- Treatment of naïve patients: update from the 12th CROI. (2005) (0)
- Antiretroviral therapy: coping with failure, planning for success. (1998) (0)
- Report from Los Angeles: the 14th Conference on Retroviruses and Opportunistic Infections (CROI). Management of treatment-naïve patients. (2007) (0)
- Antiretroviral news. (1998) (0)
- Complications of antiretroviral therapy (2005) (0)
- Current status of antiretroviral treatment interruption and intermittent therapy strategies. (2002) (0)
- Drug resistance and the treatment of experienced patients. (2002) (0)
- What's Hot in HIV (Clinical Research) (2014) (0)
- A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. (2017) (0)
- DEAR DOCTOR... WHAT ABOUT CANCER? AND OTHER QUESTIONS ANSWERED. (2015) (0)
- Board – – – – — — – — — — — — — — IAS – USA Board of Directors — — — — – — — — — — (2018) (0)
- Drug resistance and treatment of experienced patients. (2002) (0)
- International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
- IAS-USA Board of Directors (2011) (0)
- CROI 2009: a few key presentations on antiretroviral therapy. (2009) (0)
- Antiretroviral therapy: naïve patients and early therapy. (2001) (0)
- Resistance Testing in Treatment- Naive Patients Resistance to Nrtis Antiretroviral Drug Resistance and Resistance Testing (0)
- P10 The efficacy of testosterone treatment in HIV-related wasting: Does testosteronereplacement help? (1996) (0)
- Reply to Carr (2006) (0)
- Antiretroviral therapy in the experienced patient. (1999) (0)
- COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES (2016) (0)
- New antiretroviral agents. (1999) (0)
- Antiretroviral Drug Resistance and Resistance Testing 138 (2006) (0)
- Efficacy and Safety of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus (HIV)-Infected, Virologically Suppressed Older Adults: Subgroup Analysis of a Randomized, Double-Blind Switch Study (2016) (0)
- Antiretroviral therapy: rehashes, leftovers, and a pinch of new data. (1998) (0)
- Virologic Failure: True or False? (2005) (0)
- Fighting HIV -- New Antiretroviral Agents and Novel Regimens (2011) (0)
- Commentary: Primary care and public health (1993) (0)
- Plasma HIV-1 RNA and CD4+ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens: A prospective RESPOND cohort study. (2023) (0)
- The optimal use of enfuvirtide. (2003) (0)
- Antiretroviral news from the 10th EACS, Dublin. (2006) (0)
- AIDS freak-time to give up? (2001) (0)
- Antiretroviral news from the 45th ICAAC. (2006) (0)
- Report from Boston: The 12th Conference on Retroviruses and Opportunistic Infections (CROI) (2003) (0)
- Strategies for initial therapy factors affecting the choice of the first regimen (2005) (0)
- The Moore News and The Hopkins HIV Report: a time capsule: 1989-2001. (2001) (0)
- A review of dual protease inhibitor therapy. (1998) (0)
- Learning from HIV and AIDS (2005) (0)
- HIV drug guide introduction. A brief description of the drug classes and how they work. (2009) (0)
- The choice of the nucleoside backbone in initial therapy. (2004) (0)
- What is the latest news on structured interrupted treatment? Should a healthy HIV positive person consider an STI? What are the risks involved and for how long should the meds be interrupted? Is there any chance of developing resistance? (2001) (0)
- What's New in Antiretroviral Therapy (2012) (0)
- New antiretroviral agents. (2001) (0)
- ANTIRETROVIRAL THERAPY IN 2015. ONE DOCTOR'S PERSPECTIVE ON THE STATE OF HIV TREATMENT. (2015) (0)
- Current issues in initiation of antiretroviral therapy (2005) (0)
- Wellness checklist. Important things to consider when you're HIV-positive. (2008) (0)
- Tipranavir: A Viewpoint by Joel Gallant (2003) (0)
- PREVIOUSLY UNRECOGNIZED HIV INFECTION AMONG HOSPITALIZED PATIENTS (1996) (0)
- HIV infection--how to lower your risk. (2004) (0)
- Report from Buenos Aires: the 1st IAS Conference on HIV Pathogenesis and Treatment. (2001) (0)
- Antiretroviral update from the 46th ICAAC. (2007) (0)
- When to start therapy--and what to start with. (1997) (0)
- Comprar Sande's HIV/ AIDS Medicine, 2nd Edition | Nelson Sewankambo | 9781455706952 | Saunders (2011) (0)
- Safety of optimized antiretroviral therapy during allogeneic matched and haploidentical bone marrow transplant in HIV+ individuals (2015) (0)
- Routine HIV screening, Part 2: beyond testing and referral. (2009) (0)
- AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial. (2003) (0)
- Mix and match. With as many as six drug categories, more than ever, how to treat HIV can become a matter of strategy. (2010) (0)
- XV International AIDS Conference in Bangkok: antiretroviral therapy. (2004) (0)
- COBI Can Substitute for RTV in an HIV-1 Drug Regimen (2014) (0)
- Chapter 3 Future of HIV/AIDS Care in Low- and Middle- Income Countries (2008) (0)
- Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). Antiretroviral therapy: the naïve patient. (2004) (0)
- Topics in Primary Care Medicine Prophylaxis Against Opportunistic Infections in Patients Infected With the Human Immunodeficiency Virus (2005) (0)
- Track B Clinical Science (2012) (0)
- Antiretroviral therapy. (1999) (0)
- Report from ICAAC: new drugs and antiretroviral therapy for naïve patients. (2002) (0)
- Antiretroviral rounds. Is that "one pill" treatment enough? (2008) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- TUPDC0103: Gonorrhea infections diagnosed among persons living with HIV: cross matching surveillance registries to identify potential opportunities for integrated partner services-New York City, Washington D.C., Miami/Dade County and Arizona (2012) (0)
- Prophylaxis: Who, what, when, and why? (1996) (0)
- When to switch your drug combo. (1998) (0)
- Editorial comment: treating the experienced patient--when and how to use new agents. (2006) (0)
- Tipranavir: A viewpoint (2003) (0)
- Is That “One Pill” Treatment Enough? (2008) (0)
- Antiretroviral news from the Chicago: the 43rd ICAAC. (2003) (0)
- Antiretroviral rounds. Virologic failure: true or false? (2005) (0)
- HIV antiretroviral agents. (1999) (0)
- Recommendations for HIV-positive inmates. (2001) (0)
- Report from Buenos Aires on new drugs. (2001) (0)
- Current Issues in Initiating HIV Treatment (2004) (0)
- Therapy for the treatment-experienced patient. (1999) (0)
- Antiretroviral news from the 41st ICAAC. (2002) (0)
- Allogeneic Bone Marrow Transplant for HIV Patients with Hematologic Malignancies with Post-transplant Cyclophosphamide: a Feasibility Study (2020) (0)
- Risk factors for bacterial pneumonia in MV disease (1997) (0)
- START NOW. A NEW STUDY CONFIRMS THAT EVERYONE WHO IS HIV-POSITIVE SHOULD BE ON TREATMENT. (2015) (0)
- New drugs in clinical development and treatment of naive patients. (2002) (0)
- Antiretroviral news from ICAAC 2000. (2000) (0)
- 3rd IAS conference: initial therapy, switching, and new strategies. (2005) (0)
- Early treatment of HIV. (2004) (0)
- Antiretroviral therapy update from the 2nd IAS Conference. (2003) (0)
- Selected topics from the 38th annual meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana and selected topics from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Ontario, Canada. (2001) (0)
- Editorial comment: predictors of response--updating the traditional list. (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Joel E. Gallant?
Joel E. Gallant is affiliated with the following schools:
